Friday, July 10, 2026

pharma · Advanced Refractory Solid Tumors

CStone Pharmaceuticals

CStone Pharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Shanghai, CN HQ
2016 Founded
193 Employees
EMA registrant Type
Company details
Status
Public
HQ
Shanghai, CN
Founded
2016
Employees
193
Programs
1
Drugs
1
Patents
0
Intelligence · Drug Pipeline

CStone Pharmaceuticals pipeline

Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

CStone Pharmaceuticals drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

1 compounds
  1. regorafenib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.

    Target
    Discoidin domain-containing receptor 2
    Mechanism
    Fibroblast growth factor receptor 2 inhibitor